IA
ADAP

IFP Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

IFP Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,023
Closed -$1.63K – 4298
2024
Q4 		$1.63K Hold
3,023
– – ﹤0.01% 3167
2024
Q3 		$2.87K Hold
3,023
– – ﹤0.01% 2829
2024
Q2 		$2.95K Buy
+3,023
New +$3.32K ﹤0.01% 2732

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IFP Advisors's ADAP Position: Q1 2025 in Review

IFP Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 3,023 shares — an estimated $1.63K sold.

IFP Advisors first reported a position in ADAP in Q2 2024 and held it in 3 quarters. The position peaked at $2.95K in Q2 2024. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • IFP Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • IFP Advisors sold 3,023 Adaptimmune Therapeutics shares in Q1 2025, an estimated $1.63K.
  • IFP Advisors first reported a position in Adaptimmune Therapeutics in Q2 2024 and held it in 3 quarters.
  • IFP Advisors's Adaptimmune Therapeutics position peaked at $2.95K in Q2 2024.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on IFP Advisors's 13F filing for Q1 2025, filed 5 May 2025.